My 90 years have witnessed a basic transformation in the understanding of disease in terms of molecules, largely through the application of new instruments and technologies. The ultimate distillation of what really works at this level-the quantitative measurements that generate clinical insight from specimens like blood-is clinical chemistry. This field has fascinated me for a long time, partly because of my interest in inventing or improving analytical instruments, and partly as an anchor to real-world biology that is frequently missing in academic research. A second thread of interest to me is how successful research gets done, and how to know when a solitary inventor is needed and when it takes an army. Here I recount some personal experiences relevant to these interests, ranging across several fields and in organizations of widely varying scale, all ultimately linked to clinical chemistry and the human proteome.
Once Upon a Time a Long Time Ago . . . Interdisciplinary R&D has always fascinated me, and my introduction to it occurred in unusual times, during World War II. I was on active duty in the US Navy before Pearl Harbor as a Photographer's Mate 2nd Class, and was discharged at the war's end as a Lieutenant (jg) line officer, with zero instruction in between on how to be a naval officer. Despite (or because of) this fortuitous absence of formal tuition, I found that much of the fun and adventure in life lies in the cracks between disciplines, and that these cracks can be wider in large organizations (like a Navy in wartime) than smaller ones.
Flying in blimps off the Carolina coast during the height of antisubmarine warfare, it occurred to me that maybe, lacking a bombsight, we couldn't actually sink a German submarine if we found it. After developing proper instrumentation, I found experimentally this was largely true, and a proper bombsight was developed. This was the start of a series of projects that put together all sorts of technologies, raised interesting questions, and whose results were usually translated into immediate action. Transferred to the Pacific and the submarine service, I worked as a movie photographer on a project to be called "The Silent Service." This was authorized by a personal letter from Franklin Delano Roosevelt, which proved to be a magical passport to getting things done far from home. As I was shooting background footage of 2 submarines I had arranged to do the required postrefit maneuvers, a radioman came topside to say that Truman had announced use of the atomic bomb. This ended the war and with it my introduction to interdisciplinary work with effectively unlimited resources.
Suddenly I found myself at Duke University immersed in the culture of Little Science. I was taught (by a future president of the National Academy of Sciences) that proteins and nucleic acids were too complex to ever be sequenced, that chromatography, while interesting, could never be quantitative, and that no one knew for certain where and how genetic information was stored. The general attitude was very different from the "win at all costs" approach adopted in war-it was painstaking and slow, but it was biology. I began to realize I had been contaminated by the notion of Big Science, but felt I should learn to be comfortable at both ends of the Big Science-Little Science spectrum (1 ) . This pendulum has swung back and forth for me several times, and is an invigorating oscillation.
Returning to the Big end, I obtained an Atomic Energy Commission (AEC) 2 postdoctoral fellowship in the Biology Division of the Oak Ridge National Laboratory (ORNL). My PhD thesis had concerned subcellular components isolated using very simple centrifuges, and my hope at Oak Ridge was to extend this work to proteins in different subcellular particles using some new type of centrifuges, yet to be conceived. ORNL's unprecedented facilities, with staffs running into the tens of thousands, included almost all disciplines of science and engineering. Almost anything one could reasonably imagine was either available or could be designed and built quickly, even if it happened to involve nonstandard laboratory supplies like large titanium forgings. The saying, "Why use lead when gold will do?" reflects a little of the flavor.
Separation, either physical (as in the case of uranium isotopes) or chemical (as was the case for plutonium), and accurate analysis were the key technologies at most of the Manhattan Project facilities. My initial laboratories were in the same valley that housed more than a thousand giant Calutrons (preparative mass spectrometers) used to enrich kilograms of U-235. After World War II, this facility was used to go straight through the atomic table, isolating and characterizing all the stable isotopes. I wondered if the same sort of effort and philosophy could be adapted to the comfortable field of biology? Could one ever separate the components of living cells into a "parts list" for man? If so, it should provide a powerful way to study and ultimately understand disease.
The Molecular Anatomy Program
As it happened, the major nuclear weapons laboratories needed new missions after the success of the Manhattan Project. I suggested one in the winter of 1959 -60 entitled "The Cell Fractionation Project," an effort to separate and characterize all the molecules in cells, which much later became the Molecular Anatomy Program. It appealed to nearly everyone at ORNL except my fellow biologists, who did not like big projects (unless it was mouse genetics). We had thought about sequencing DNA but were assured by biochemists that, while RNA could in theory be sequenced, DNA simply could not be for purely chemical reasons (this was before the discovery of restriction enzymes or dideoxy sequencing). So the thinking focused on proteins.
Protein fractionation had been advancing on multiple fronts during the preceding decades. In the 1930s and '40s, Svedberg had developed the analytical ultracentrifuge which showed, unexpectedly, that proteins had well-defined masses, and Tiselius, who once described to me how he had inadvertently left his gardening shoes on when he went to hand out Nobel Prizes, had developed electrophoresis by which plasma proteins could be classified into 4 discrete groups (albumin and the famous ␣, ␤, and ␥ globulins). By the mid1950s, Sober and Peterson had begun to fractionate proteins on cellulose columns, and Waldo Cohn, who had pioneered separating fission products on ionexchange columns at Oak Ridge, began to work on nucleic acids, convincing Moore and Stein to use ion exchange in place of starch columns for amino acid analysis. Precipitation was explored in parallel by Gerhard Schwick at the Behring Institute in Germany. He isolated dozens of human plasma proteins, made antibodies to them, and distributed these worldwide. This approach with distributable reagents allowed specific protein assays to be performed on clinical samples, thus starting immunodiagnostics on the present road to broad coverage of the human proteome. While largely forgotten in the field of proteomics, this effort has survived through multiple commercial marriages with Hoechst, then Dade Behring, and finally Siemens Diagnostics.
My own work really began with the invention of the zonal centrifuge (2 ) to fractionate subcellular particles. In this device, the volume limitation inherent in swinging bucket gradient separations was surmounted by using large, hollow, bowl-shaped (zonal) rotors. In these, gradients and samples were caused to flow through rotating seals into a rotor spinning at low speed and then accelerated to maximum speed to effect a separation based on either sedimentation rate or isopycnic banding density (or, in later designs, both). This was followed by deceleration to a low speed and recovery of the gradient as isolated fractions by displacement from either the center or the edge. I had designed and built a slow and crude proof-of-principle zonal rotor and then had arranged to have one built commercially, which was unfortunately unstable at high speed. Instability of a large rotor at 40 000 rpm, especially if it leads to catastrophic self-disassembly (a phrase we adopted from Los Alamos, which knew about such things) is undesirable. We needed real engineering expertise in rotating systems, an unusual discipline but one that was by chance very popular at Oak Ridge. Gas centrifugation for uranium enrichment had been tried and abandoned in 1943 because of its high cost. Subsequently it was discovered that a captured German Luftwaffe engineer named Guernot Zippe had designed for the Russians a remarkably simple centrifuge that used very little power and was surprisingly efficient. The need to catch up with this development accounted for the presence of an engineering staff working at top speed (in all meanings of the phrase) in Oak Ridge. The resulting urgency, money, and minimal administration helped as usual to eliminate the curse of delayed gratification, chief destroyer of creativity. We built (and sometimes blew up) a lot of centrifuges, and they became progressively better at separating biological materials.
The Joint NIH-AEC Zonal Centrifuge Project
In the early '60s, Robert Huebner of the National Institute for Allergy and Infectious Diseases and others
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Reflection found that many animal cancers were caused by viruses, especially if the viruses were given to newborns. Numerous groups were set up across the US to attempt to isolate cancer viruses, grow them in culture, test them in primates, and see if a cancer vaccine was possible. When these efforts failed to find culturable human cancer viruses, I suggested to Huebner that we try to isolate them by physical means, using density gradient centrifugation, instead of relying on growth in culture. If this were successful, then similar physical methods could be used for large-scale purification of virus for a vaccine. The US Food and Drug Administration (FDA) was insistent that any killed virus vaccine should contain no (or at least very little) cancer cell DNA to be sure that the vaccine itself did not cause cancer. To make a pure virus vaccine for large-scale human use by physical means would require a liquid centrifuge of a size never before built.
Testing these systems required large quantities of virus, and neither Sabin nor Salk, who were very cooperative, had poliovirus in the quantities we needed (milligrams rather than infectious doses). Initially we settled on seawater obtained from the Woods Hole laboratory and discovered to our surprise that the ocean has about the same viral load as a viremic human's blood (3 ). For more realistic development, though, we obtained a batch of human viral vaccine that did not meet FDA standards and thus could not be sold. To avoid risk of viral contamination to ORNL's enormous mouse genetics facility, we relocated the centrifuge development program to the most distant site available on the Oak Ridge reservation, which was, fortunately, right next to the giant Oak Ridge Gaseous Diffusion Plant, locus of the gas centrifuge project. Our "lab" was a mothballed power plant, whose Manhattan Project pedigree was visible on the wall as a framed single-page purchase order for "One coal-fired steam-driven electrical generating plant, 237 megawatt." It had railroad tracks coming in one end of the 100-yard long main floor and a 30-ton overhead crane for moving large equipment, among other conveniences.
We needed a general theory on which to base our search for viruses in tissue homogenates. To see the possibilities of such a separation, I plotted the sedimentation coefficient S against the banding density for viruses and for the major subcellular particles and discovered that viruses generally are found in the middle of this plot in an otherwise thinly populated area away from nuclei, mitochondria, proteins, etc. (4 ). This plot was key to the whole project, and it suggested that we combine sequentially rate and banding techniques into one 2-dimensional (2D) S-separation. This theoretical plot was converted into a real one in which bacteriophage were recovered from rat liver and other tissue homogenates (5 ), perhaps the first integrated highresolution 2D separation in biology.
As it became clear that no cancer viruses were being found around which to design a vaccine purification system, I decided that we should work on an existing vaccine that required better purification. We would thus be ready if a human cancer virus was actually found. At that time, egg-grown influenza vaccines contained appreciable amounts of egg proteins, resulting in many deaths from anaphylactic shock each year and the requirement that they be given under close medical supervision. We approached Eli Lilly about designing a centrifugal system specifically to purify influenza vaccine. Their batch size was 100 L, and the purification run had to be completed in an 8-h day. Knowing these parameters and both the sedimentation coefficient and banding density of influenza, it was possible to design a rotor system that used continuous flow to band the virus from 100-L batches in a narrow gradient that could be recovered at the end of a run. The result was the K-II continuous-sample-flow-with-banding ultracentrifuge (6 ). Use of this centrifuge essentially eliminated vaccination deaths from anaphylactic shock and allowed vaccination in supermarkets under minimal supervision. Almost 40 years later, it is still in use around the world with minimal modifications for vaccine manufacture, and we have recently proposed its use to isolate the viral load from 100-L batches of pooled diagnostic serum discarded in clinical reference laboratories each week (7 ) . The viral DNA and RNA, concentrated and free of host nucleic acids, could then be shotgun-sequenced to screen for new viruses, while providing a running index of the known viruses "going around."
The Centrifugal Fast Analyzer (GeMSAEC)
High-resolution separations of cell components generated many fractions. To monitor specific enzyme activities across these fractions, we initially used Technicon Autoanalyzers borrowed from clinical chemistry. However, I once casually remarked to Leonard Skeggs (who had invented most of the original Technicon segmented-flow bubble system) that there must be some other way to automate clinical chemistry. He answered that this was not possible. I thought about this a lot. It was my introduction to clinical chemists and clinical chemistry.
The problem was to build a random access system for assembling reactions between samples and reagents in parallel rather than serially. It turned out that centrifugal force is an excellent way to measure and move small liquid volumes, while cuvettes at the edge of a rotor spinning beneath a fixed photometer provide frequent optical measurements that yield very accurate reaction rates. The data rate was sufficiently high, in fact, that we needed direct connection to a "minicomputer" like the Digital Equipment Corporation PDP-8 to capture it. Acquiring these in the early '70s was extremely difficult given ORNL's centralized mainframe mentality, but we eventually learned that a PDP-8 labeled a "digital controller" caused no notice. The resulting instrument was named the GeMSAEC (for General Medical Sciences-Atomic Energy Commission) centrifugal fast analyzer ( Fig. 1) (8 ) . It was a worldwide commercial success for Roche (the Cobas Bio), Instrumentation Labs, Aminco, Electronucleonics, and Union Carbide, and in many cases, it did supplant Technicons. New implementations continue to arise (e.g., the Gyros system), and it still may be the best system for very accurate rapid photometric measurements.
Despite the success of zonal centrifuges and the centrifugal fast analyzer, the National Cancer Institute's conclusion that human cancer was only rarely due to viral infection, coupled with AEC's waning interest in biotechnology, led me to move to the Medical University of South Carolina. I was extremely fortunate to be joined in Charleston by my son, Leigh Anderson, who had completed a PhD at the University of Cambridge under Nobel Prize winner Max Perutz and done a mini-postdoc there with Sydney Brenner. Leigh had read O'Farrell's famous paper on 2D electrophoresis (9 ) and had deciphered the procedures. Together we set up a small laboratory and got a $5000 state research grant to support us (probably the most important grant we ever got). O'Farrell had worked out a procedure which was, initially, something of a curiosity. In Charleston, Leigh assembled a system and identified the major plasma proteins by immunoprecipitation with the whole collection of Behring antisera (10 ) . The microheterogeneity of plasma proteins, now called posttranslational modification, was immediately evident, presenting many glycosylation isoforms, precursors, and proteolytic cleavage products. Protein changes occurring on clotting were immediately clear (Fig. 3) (11 ) . We found the 2D pattern of plasma proteins to be strikingly reproducible and immediately informative to an expert, but without quantification it was more meaningful to a pathologist than a clinical chemist.
It became clear that to fully exploit 2D technology, we needed once again the resources of a National Laboratory, and fortunately this coincided with an opportunity to join the biology division at Argonne near Chicago. For several months, we worked in Charleston during the week and at Argonne on weekends, designing together what we called the Iso-Dalt system for casting and running large sets of 2D gels in parallel (12, 13 ) . Our initial image analysis system was an optical comparator designed to visually compare 2 gels by flickering between them, a technique used by astronomers to discover the planet Pluto. This was soon superseded by an electronic camera and large minicomputers for image processing (14 ) . Using these tools we explored the protein patterns (later called proteomes) of human lymphocytes (15 ) , red cells (16 ), urine (17 ), platelets (18 ) , saliva (19 ) , muscle (20 ) , semen (21 ), milk (22 ) , as well as rat liver (23 ) and many other samples. We were fortunate to host the first 2 major international symposia on 2D proteomics (the first at Ar- At right is a portion of the minicomputer system used to acquire and process optical absorbance measurements from cuvettes at the edge of the spinning rotor.
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Perhaps naively (but perhaps not-this was before Sanger devised effective DNA sequencing), we felt that enumeration of all the human proteins by cell fractionation and 2D electrophoresis was the only way to replicate in biology the unifying effect that the periodic table had achieved in chemistry. This idea was formulated as the "Human Protein Index" (24 ) , aimed at providing a foundation for pharmacology, toxicology, diagnostics, and ultimately what is now systems biology. Such an effort would require large resources, and so, with several colleagues, we suggested formation of a Human Protein Index (HPI) Project, along the general lines we had planned in Oak Ridge, to promote and integrate this work. Senator Alan Cranston, who was the Majority Whip of the US Senate at the time, was interested in biomedical research with emphasis on aging and held informal meetings on various biomedical topics in his office in the Capitol on Sunday mornings. Through these discussions, a Human Protein Index Task Force was organized, and in late 1980, a report was produced laying out the scope and size of a systematic attack on the human proteome (25 ) . However, 1980 also brought Reagan's election and a new cast of characters much less receptive to HPI and more receptive to the Strategic Defense Initiative.
Large Scale Biology Corp
Outside the National Laboratory orbit, it appeared that systematic study of proteins was poised to become a critical platform technology in the pharmaceutical industry-at that time, the closest thing in biology to the Big Science approach of the National Laboratories. We left Argonne in 1984 and set up Large Scale Biology Corp. (LSBC) to perfect 2D gels and protein index databases, and the company evolved over the years toward a merger with friends in tobacco-based protein expression and finally a successful initial public offering (IPO) in the boom year 2000. With an automated 2D electrophoresis system running 100 samples/day, we explored drug effects in tissues (particularly rat liver, the favorite sandbox of toxicology) and continued to peel the onion of human plasma. Using a recycling-affinity chromatography approach we had developed at Oak Ridge (26 ), we prepared the first mixed-antibody columns that subtracted the abundant plasma proteins [later used as the basis of the molecular adsorbent recirculating system (MARS) depletion columns (27 ) ], which, with additional fractionation steps, extended the reach of 2D from the 50 most abundant plasma proteins to more than 300 (28 ) . The advent of mass spectrometry for protein identification allowed us finally to name all the blue or fluorescent spots we had seen changing in hundreds of drug studies, and extensive image analysis extracted quantitative measures of changes in specific protein abundance. During this period, I continued to pursue a sideline in centrifugal systems, developing a large-scale centrifugal oligonucleotide synthesizer for antisense drugs (29 ) and a microscale centrifuge tube for collecting viruses from small clinical samples, banding them or pelleting them in nanoliter volumes to get a plasma "virocrit" measurement (30 ) . This technology has advanced to yield purified and concentrated viruses from fresh serum in about 2 h in quantities that match the requirements of single-molecule sequencers (31 ), thus paving the way toward same-day isolation and sequencing of human viral pathogens.
The Promise of Proteomics for Clinical Chemistry Today
Although it is a little late for my own convenience, the broad outline of a serious approach to understanding the human proteome and mining it for diagnostics has recently begun to emerge. To start with, the availability of a usable human genome has provided the means to organize the proteins, and perhaps most importantly, shown us that there are really only about 20 300 of them (32 ) rather than the 100 000 -150 000 we were once told to expect. Setting aside the myriad splice variants and posttranslational forms to focus on a representative protein product of each gene, this sounds like a tractable number to look at over a decade or so. Indeed, several large-scale studies are already underway, beginning with an effort to systematically determine the 3D structures of all the important proteins. Perhaps because x-ray crystallography is really physics, this is being done at unmistakably Big Science facilities like the Advanced Photon Source at Argonne (in reality a large particle accelerator). The resulting structure library should provide a workable foundation for understanding protein:protein interactions (the "interactome") and thus the mechanisms of cell regulation and signaling. In Sweden, Uhlen (33 ) and Ponten are approaching 50% completion of a project making polyclonal antibodies to each human protein, and then immunostaining microtome sections to see where these proteins are in normal and diseased tissues. Given continued success in this effort, a broad foundation for major clinical advances in anatomic pathology will be created.
Whereas the structural aspects seem to be wellcovered, protein quantification-the real connection with clinical chemistry-appears only now to be falling into place. A new generation of mass spectrometry tools for peptide quantification (34, 35 ) is emerging that can ultimately rival immunoassays in terms of sensitivity and precision, while adding absolute structural specificity and facile multiplexing without interference (36 ) . Most importantly, this technology makes it possible to rapidly develop specific assays for proteins starting from genomic sequence data, enabling a Human Proteome Detection and Quantification (hPDQ) project to create quantitative, multiplexable, and specific assays for all human proteins (37 ) . Such a suite of assays could, in turn, jumpstart the present anemic protein biomarker pipeline and might even translate directly into the clinical laboratory (where mass spectrometry is gaining acceptance for better measurement of steroids, immunosuppressants, and Vitamin D). It seems to me that this kind of project, opening up basic clinical research and clinical chemistry at the same time, is even more significant than the human genome effort, and calls for a period of Big Science thinking in the protein community. If all this comes to pass, it will constitute a revolution in clinical chemistry, placing it at the forefront of biological knowledge generation and at the heart of clinical decision-making. That would be progress.
